India’s controversial compensation rules could lead to clinical trials "standstill"
This article was originally published in SRA
Executive Summary
India's recently gazetted trial compensation norms go against the very "tenets of science" putting at risk the future of the country as a favorable destination for such studies, according to a clutch of industry pundits1.